Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The stated indication that enasidenib (IDHIFA) is for adult patients with relapsed or refractory AML with an IDH2 mutation detected by an FDA-approved test is directly supported by the provided label (Section 1.1).
Category Scores
Accurate Statements
Enasidenib (IDHIFA) is indicated for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation as detected by an FDA-approved test.
Label Section 1.1: “IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.”
The provided label citation (Section 1.1) directly supports the claim including IDHIFA, adult patients, relapsed/refractory AML, IDH2 mutation, and detection by an FDA-approved test.
Same Section 1.1 quoted above.
Unsupported Statements
Contradictions
Important Omissions
No evaluation was provided for other label elements (e.g., contraindications, boxed warnings, dosing/administration, warnings/precautions, drug interactions, adverse reactions, monitoring, storage/handling, or further description/mechanism).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantive claim evaluated is the on-label indication, which is directly supported by the provided FDA label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Evaluation scope appears limited to the indication; other label sections were not assessed.
Suggested Improvement
If additional claims are to be evaluated, provide corresponding label excerpts and assess alignment for contraindications, warnings/precautions, dosing/administration, interactions, adverse reactions, and monitoring.